Canada's Knight Therapeutics Q1 revenue jumps 69%, beats estimates

Knight Therapeutics

07/05/2026 11:43

Overview

Canada pharmaceutical firm's Q1 revenue rose 69% yr/yr, beating analyst expectations

Company raised 2026 revenue guidance on strong product performance

Outlook

Knight raises 2026 revenue guidance to C$510 mln-C$525 mln from C$490 mln-C$510 mln

Company expects 2026 adjusted EBITDA to be about 15% of revenues

Result Drivers

PORTFOLIO ACQUISITIONS - Incremental revenues from Paladin and Sumitomo portfolios drove revenue growth

PROMOTED PRODUCTS - Growth in promoted products, including recent launches, contributed significantly to revenue

PRODUCT LAUNCHES AND DELIVERIES - Higher Ambisome deliveries to the Ministry of Health and multiple new product launches boosted results

Company press release: ID:nGNX5dQ3BF

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
C$148.44 mln
C$113.70 mln (4 Analysts)
Q1 Net Income
C$13.17 mln
Q1 Operating Expenses
C$58.53 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)